Exchange Capital Management Inc. Sells 38,138 Shares of Core Laboratories Inc. $CLB

Exchange Capital Management Inc. reduced its stake in shares of Core Laboratories Inc. (NYSE:CLB) by 51.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 35,489 shares of the oil and gas company’s stock after selling 38,138 shares during the period. Exchange Capital Management Inc.’s holdings in Core Laboratories were worth $409,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its stake in Core Laboratories by 19.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company’s stock valued at $1,037,000 after purchasing an additional 11,438 shares during the last quarter. Assetmark Inc. raised its stake in shares of Core Laboratories by 92.5% in the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company’s stock valued at $43,000 after buying an additional 1,387 shares during the period. Public Sector Pension Investment Board raised its stake in shares of Core Laboratories by 26.9% in the first quarter. Public Sector Pension Investment Board now owns 148,476 shares of the oil and gas company’s stock valued at $2,226,000 after buying an additional 31,485 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Core Laboratories by 1.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 254,005 shares of the oil and gas company’s stock valued at $3,808,000 after buying an additional 3,357 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Core Laboratories by 972.6% during the 1st quarter. GAMMA Investing LLC now owns 68,669 shares of the oil and gas company’s stock worth $1,029,000 after acquiring an additional 62,267 shares during the period. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CLB. Zacks Research upgraded Core Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, July 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Core Laboratories in a research note on Saturday, September 27th. Finally, Stifel Nicolaus reduced their price objective on shares of Core Laboratories from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, July 16th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $12.50.

Core Laboratories Price Performance

CLB stock opened at $12.18 on Friday. The firm has a 50 day moving average of $11.56 and a 200-day moving average of $12.04. The firm has a market capitalization of $571.12 million, a P/E ratio of 19.65, a price-to-earnings-growth ratio of 3.62 and a beta of 1.38. Core Laboratories Inc. has a 12 month low of $9.72 and a 12 month high of $21.83. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.01. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The business had revenue of $130.16 million for the quarter, compared to analyst estimates of $129.19 million. During the same quarter in the prior year, the firm posted $0.22 EPS. Core Laboratories’s revenue was down .3% on a year-over-year basis. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. As a group, sell-side analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Monday, August 4th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is currently 6.45%.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.